Related Experiment Video
Updated: Dec 15, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Chronic kidney disease as a cardiovascular risk factor
Rafael Carmena1,2, Juan F Ascaso1,2, Josep Redon3,4
1Department of Medicine, INCLIVA, University of Valencia, Valencia.
Insights
Managing chronic kidney disease (CKD) involves aggressive treatment of cardiovascular risk factors like hypertension, dyslipidemia, and diabetes. Early intervention and lifestyle changes are crucial for both cardiovascular and kidney protection in CKD patients.
Area of Science:
- Nephrology
- Cardiology
- Public Health
Background:
- Chronic kidney disease (CKD) significantly increases cardiovascular disease (CVD) risk and mortality.
- CKD is recognized as a marker for high or very high cardiovascular risk, necessitating prompt management.
- Cardiovascular risk factors, including hypertension, dyslipidemia, and diabetes, are prevalent and critical in CKD patients.
Purpose of the Study:
- To outline essential strategies for managing cardiovascular risk in patients with chronic kidney disease.
- To emphasize the importance of lifestyle modifications and pharmacological interventions for combined cardiovascular and kidney protection.
- To provide updated recommendations for blood pressure, diabetes, and dyslipidemia management in CKD.
Main Methods:
- Review of current guidelines and evidence for managing cardiovascular risk factors in CKD.
- Analysis of recommended lifestyle interventions: smoking cessation, weight reduction, physical activity, and dietary changes.
- Evaluation of pharmacological strategies for hypertension, diabetes (including iSGLT2 and GLP-1RA), and dyslipidemia (statins, ezetimibe, PCSK9 inhibitors).
Main Results:
- Lowering office blood pressure (BP) to 130/80 mmHg or lower is recommended, with out-of-office monitoring advised.
- Diabetes management includes lifestyle changes and metformin for prediabetes, with iSGLT2 and GLP-1RA for type 2 diabetes (T2D) at high cardiovascular risk.
- Specific LDL-C goals and statin therapies are recommended based on CKD stage, with consideration for PCSK9 inhibitors in advanced stages.
Conclusions:
- Integrated management of cardiovascular risk factors is paramount for patients with CKD.
- Lifestyle modifications and tailored pharmacological treatments are essential for improving outcomes.
- Adherence to recommended treatment goals for BP, diabetes, and dyslipidemia can mitigate cardiovascular and renal complications.
Abstract:
: Chronic kidney disease (CKD) is a public health threat with impact in cardiovascular risk. All forms of cardiovascular disease and mortality are more common in CKD. Treatment of cardiovascular risk factors, hypertension, dyslipidemia and diabetes is essential for cardiovascular and kidney protection. CKD is a marker of high or very high cardiovascular risk and its presence require early treatment and specific goals. Lifestyle is a pivotal factor, stopping smoking, reducing weight in the overweight or obese, starting regular physical exercise and healthy dietary pattern are recommended. Office BP should be lowered towards 130/80 mmHg or even lower if tolerated with sodium restriction and single pill combination, including angiotensin system blocker. Out-of-office BP monitoring, mainly 24-h assessment, is recommended. Diabetes requires treatment from the moment of diagnosis, but prediabetes benefits with lifestyle changes and metformin in patients stage 2 and 3a. iSGLT2 and GLP-1RA are initially recommended in T2D patients with high or very high cardiovascular risk. Concerning dyslipidemia, for patients in stage 4, LDL-C 55 mg/dl or less (1.4 mmol/l) and an LDL-C reduction of 50% or less from baseline is recommended. In stage 3, LDL-C goal is 70 mg/dl or less (1.8 mmol/l) and an LDL-C. reduction of at least 50% from baseline. Statins are the lipid-lowering therapy of choice with or without ezetimibe. Higher doses of statins are required as GFR declines. Available evidence suggests that combined PCSK9 inhibitors with maximally tolerated dose of statins may have an emerging role in treatment of dyslipidemia in CKD patients.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:24Chronic Kidney Disease II: Clinical Manifestations
01:18Chronic Kidney Disease IV: Nursing Management
01:28Chronic Kidney Disease III: Interprofessional Care
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:29Acute Kidney Injury III: Clinical Manifestations